The Institute of Cancer Research: Royal Cancer Hospital;Kudos Pharmaceuticals Limited
发明人:
Alan Ashworth,Stephen Jackson,Niall Martin,Graeme Cameron Murray Smith
申请号：
US15593865
公开号：
US20170319543A1
申请日:
2017.05.12
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
